v3.26.3
Commitments and Contingencies - License Agreements (Details) - Related party
 1 Months Ended
Sep. 07, 2021
USD ($)
shares
Nov. 01, 2019
USD ($)
shares
Mar. 31, 2023
Mar. 27, 2023
item
Series A Preferred stock        
Commitments and Contingencies        
Shares value upon initiation of Phase III Clinical Trials $ 100,000      
KMPL        
Commitments and Contingencies        
Number of clinical test drug candidates granted for the use, sale, or offer of sale in India | item       2
Percentage of clinical trials fees     30.00%  
Percentage of royalty fee     70.00%  
TheraCour Pharma Inc        
Commitments and Contingencies        
Percentage of net sales allocated for royalty payments (in percent)   15.00%    
Issuance of shares | shares   75,000    
Cash upon completion of Phase I Clinical Trials   $ 1,500,000    
Cash upon completion of Phase II Clinical Trials   2,500,000    
Cash upon completion of Phase III Clinical Trials   $ 5,000,000    
TheraCour Pharma Inc | Series A Preferred stock        
Commitments and Contingencies        
Percentage of net sales allocated for royalty payments (in percent) 15.00%      
Issuance of shares | shares 50,000      
Cash upon completion of Phase I Clinical Trials $ 2,000,000      
Cash upon completion of Phase II Clinical Trials 2,500,000      
Cash upon completion of Phase III Clinical Trials $ 5,000,000      
Number of shares issuable upon execution of agreement | shares 100,000      
Threshold Period for Issuance of Shares Upon Execution of Agreement 30 days      
Stock Issued During Period Value New Issues Initiation Of Phase1 Clinical Trials $ 1,500,000      
Shares value upon completion of Phase III Clinical Trials $ 500,000